Search research articles
Contact Us
Filters
Showing results (211-220 of 229) with videos related to
Page
of 23
Sort By:
Plos Pathogens
|
November 8, 2012
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules
Steven Johnson, Lionel Tan, Stijn van der Veen, et al.
Nature Reviews. Nephrology
|
January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal disease
Richard J H Smith, Gerald B Appel, Anna M Blom, et al.
American Journal of Nephrology
|
November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Steven D Podos, Howard Trachtman, Gerald B Appel, et al.
Immunity
|
February 24, 2017
Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation
Bertrand Calippe, Sebastien Augustin, Fanny Beguier, et al.
Immunity
|
July 27, 2023
Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis
Máté G Kiss, Nikolina Papac-Miličević, Florentina Porsch, et al.
Cancer Immunology Research
|
May 27, 2021
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
Marie V Daugan, Margot Revel, Romane Thouenon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
R I Haddad, E Massarelli, J J Lee, et al.
American Journal of Nephrology
|
November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Carla Nester, Gerald B Appel, Andrew S Bomback, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 23, 2021
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes
Edwin K S Wong, Kevin J Marchbank, Hannah Lomax-Browne, et al.
Journal of the American Society of Nephrology : JASN
|
May 6, 2024
Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy
Marie-Sophie Meuleman, Florent Petitprez, Matthew C Pickering, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 229) with videos related to
Sort By:
Page
of 23
Plos Pathogens
|
November 8, 2012
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules
Steven Johnson, Lionel Tan, Stijn van der Veen, et al.
Nature Reviews. Nephrology
|
January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal disease
Richard J H Smith, Gerald B Appel, Anna M Blom, et al.
American Journal of Nephrology
|
November 21, 2022
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Steven D Podos, Howard Trachtman, Gerald B Appel, et al.
Immunity
|
February 24, 2017
Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation
Bertrand Calippe, Sebastien Augustin, Fanny Beguier, et al.
Immunity
|
July 27, 2023
Cell-autonomous regulation of complement C3 by factor H limits macrophage efferocytosis and exacerbates atherosclerosis
Máté G Kiss, Nikolina Papac-Miličević, Florentina Porsch, et al.
Cancer Immunology Research
|
May 27, 2021
Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade
Marie V Daugan, Margot Revel, Romane Thouenon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 2019
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
R I Haddad, E Massarelli, J J Lee, et al.
American Journal of Nephrology
|
November 24, 2022
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
Carla Nester, Gerald B Appel, Andrew S Bomback, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
September 23, 2021
C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes
Edwin K S Wong, Kevin J Marchbank, Hannah Lomax-Browne, et al.
Journal of the American Society of Nephrology : JASN
|
May 6, 2024
Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy
Marie-Sophie Meuleman, Florent Petitprez, Matthew C Pickering, et al.
Page
of 23